Venn Appointment New Chairman

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Allan Wood as Chairman to the Board with effect from 20 September 2016 taking over from Tony Richardson who has been acting as Executive Chairman since January 2016.

Allan Leigh Wood, aged 52, was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. Since then he has held a number of positions as a Non-Executive Director and Chairman of multiple companies across a broad range of fields where he has acquired skills that will benefit Venn.

Tony Richardson, Chief Executive Officer of Venn said: “I am delighted to welcome Allan to Venn. Allan has extensive relevant experience in scaling businesses in health services and related sectors and I believe will add significant value as we seek to continue our current growth trajectory. Allan’s experience includes both organic business growth and M&A and together we can continue to build a successful and sustainable business for shareholders.”

Read more at VennLifeSciences.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.